Results 111 to 120 of about 110,931 (189)

First-line pembrolizumab plus chemotherapy versus bevacizumab plus chemotherapy in response and survival outcomes in PD-L1-negative advanced non-squamous NSCLC: a retrospective comparative cohort study. [PDF]

Transl Lung Cancer Res
Huang K, Pan S, Dong H, Lu H, Yan B, Qian J, Chu T.   +6 more
europepmc   +1 more source

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

, 2009
Dimitrios A Karagiannis1, Ioannis D Ladas2, Efstratios Parikakis1, Ilias Georgalas2, Athanasios Kotsolis2, Giorgos Amariotakis1, Vasileios Soumplis1, Panagiotis Mitropoulos11Ophthalmiatrio Eye Hospital of Athens, Athens, Greece; 2First Department of ...
Efstratios Parikakis, Ioannis D Ladas, Dimitrios A Karagiannis, et al.   +3 more
core  

Therapeutic Plasma Exchange for Removal of Bevacizumab: A Case Series. [PDF]

J Clin Apher
Gopu SS, Patell R, Uhlmann EJ, Vega RA, Carney BJ.   +4 more
europepmc   +1 more source

Systemic Bevacizumab for Severe Bleeding From Acquired Gastrointestinal Vascular Malformations. [PDF]

Am J Hematol
Ayad NE, Anderson JR, Dey B, Leaf RK, Song AB, Al-Samkari H.   +5 more
europepmc   +1 more source

Disproportionality analysis of off-label intravitreal bevacizumab in the FDA Adverse Event Reporting System database. [PDF]

Ther Adv Drug Saf
Contreras-Salinas H, Vázquez-Beltrán JC, García-Sánchez G, Quirarte-Justo S, Gómez-Macías SDC, Rodríguez-Herrera LY.   +5 more
europepmc   +1 more source

Immunotherapy Rechallenge in HCC: A Second Chance for Response? [PDF]

Liver Int
Da Fonseca LG, Guerrero A, Muñoz-Martínez SG.   +2 more
europepmc   +1 more source

Transcriptome signatures for the identification of bevacizumab responders in ovarian cancer. [PDF]

Genome Med
Zolotareva O, Legler K, Tsoy O, Esteve A, Sergushichev A, Sukhov V, Baumbach J, Eylmann K, Qi M, Alawi M, Kommoss S, Schmalfeldt B, Oliveira-Ferrer L.   +12 more
europepmc   +1 more source

Association Between Treatment-Emergent Pancreatic Volume Loss and Survival Outcomes in Patients with Metastatic Colorectal Cancer Receiving Bevacizumab. [PDF]

Medicina (Kaunas)
Ayyıldız Sevim H, Şahinli H, Uyar GC, Çelik S, Karatlı S, Akgüner G, Turhan B, Duran Kaymak S, Kavak RP, İmamoğlu Gİ.   +9 more
europepmc   +1 more source

Differential Tumor Response and Conversion Outcomes Associated with First-Line Biologic Strategies in Liver-Limited <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. [PDF]

Oncol Res
Chiang SW, Chen MC, Lin CL, Huang YL, Chiang FF, Yang SF.   +5 more
europepmc   +1 more source

First-Line Maintenance Therapy Patterns in BRCA Wild-Type, HRD-Negative or Biomarker-Unknown Advanced Epithelial Ovarian Cancer: A Five-Country European Real-World Study by APLUSA. [PDF]

Cancers (Basel)
Uccello M, Boussios S, Maï C, Worton H, Bazire A, de Buhren B.   +5 more
europepmc   +1 more source